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1Chapter
Overview of T-cell Lymphomas
Nagavalli Somasundaram and Soon Thye Lim
Abstract
T-cell lymphomas are a mixed bag of diseases with a similar origin but diverse 
in biology and behavior. This review aims to highlight the key changes to the WHO 
classification and summarize the therapeutic paradigm as of the time of writing in 
November 2018.
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1. Introduction
T- and natural killer (NK)-cell lymphomas are a heterogeneous group of 
lymphoproliferative diseases that represent 10–15% of non-Hodgkin lymphomas 
(NHL). T-cell lymphomas in general have worse outcomes as compared to their 
B-cell counterparts. Over recent years, the understanding of the different subtypes 
of T-cell lymphoma has led to advances in management.
2. Background
2.1 WHO classification
T- and NK-cell lymphomas can be subclassified according to nodal, extranodal, 
cutaneous, or leukemic subtypes based on the 2008 World Health Organization 
(WHO) classification of lymphoid malignancies (Table 1) [1]. The 2016 update of 
the WHO classification saw the addition of three provisional entities and changes 
in designation to five entities, reflecting the advancements in the understanding of 
this group of diseases [2, 3]. The major changes are highlighted below.
The update in the classification saw follicular T-cell lymphoma coming under the 
umbrella of angioimmunoblastic T-cell lymphoma (AITL), given the common genetic 
mutations such as TET2, IDH2, DNMT3A, RHOA, and CD28 and fusions such as 
ITK-SYK and CTLA4-CD28 nodal peripheral T-cell lymphoma (PTCL), previously 
classified under peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) was 
reclassified under the AITL classification given the similar genetic landscape.
The diagnosis of PTCL NOS is made when a lymphoproliferative disorder is of 
the T-cell lineage without any distinctive features that fit into the subtypes. Two 
distinct molecular subgroups have been identified in PTCL NOS with differing 
clinical outcomes and prognosis. High expression of transcription factor GATA3 
was associated with worse clinical outcomes, while TBX2 expression enriched by 
IFNgamma and NfKB pathways was associated with better survival. These findings 
provide insight into a disease which has been a diagnosis of exclusion, with poor 
clinical outcomes and minimal advances in treatment.
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The ALK-negative subtype of anaplastic large cell lymphoma (ALCL) has been 
identified as a distinct entity. The expression of TNFRSF8, BATF, and TMOD1 differ-
entiates ALK-negative ALCL from PTCL NOS. ALK-negative ALCL is a heterogeneous 
disease with a third harboring DUSP22 rearrangement and another 8% having TP63 
rearrangements. The former has a 90% 5-year overall survival (OS) rate, mirroring 
the outcomes of its ALK-positive ALCL counterpart, while the latter is associated with 
a 5-year OS rate of 17%. The subset of ALK-negative ALCL which does not carry both 
the rearrangements has outcomes straddling in between these two extremes.
Breast implant-associated ALCL has been recognized as a provisional new 
entity—this is a unique variant in that the lymphomatous cells are confined to the 
seroma fluid surrounding the implant without capsular invasion. As such, surgi-
cal removal of the implant including the capsule is often curative, with systemic 
therapy being rarely indicated.
The 2008 classification included enteropathy-associated T-cell lymphoma 
(EATL) types 1 and 2 as part of the intestinal T-cell lymphoma spectrum. In the 
latest revision, this has been amended to EATL and monomorphic epitheliotropic 
intestinal T-cell lymphoma (MEITL). EATL is a condition linked to coeliac disease 
and is more common among northern Europeans. MEITL, on the other hand, is 
a disease of Asians and Hispanics with no associations with coeliac disease. At a 
molecular level, EATL is predominantly characterized by T-cell alpha/beta receptor 
expression, while MEITL has predominantly T-cell gamma/delta receptors being 
expressed. The nuclear expression of megakaryocyte-associated tyrosine kinase, 
MYC amplification, and alterations in SETD2 and JAK STAT pathways are other 
genetic events characteristic of MEITL [4].
2.2 Epidemiology
PTCL NOS forms about 25% of T-cell lymphomas, followed by angioimmuno-
blastic T-cell lymphomas (18%), NK-/T-cell lymphomas (NKTL—10%), and adult 
T leukemia/lymphoma (9%) [5]. Geographic variation in the various subtypes 
Table 1. 
Classification of T-cell lymphoma.
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of T-cell lymphoma has been reported. The international T-cell lymphoma study 
reported rates of PTCL and NKTL to be 5–10% in Western countries and 10–20% 
in Asian countries. However, Au et al., in a study of 148 patients, reported similar 
frequencies of T-cell lymphomas in the Western and Asian populations [6]. This was 
supported by another study analyzing the differences between PTCL and NKTL 
[7]. The perceived difference in the disparate frequencies of these diseases may have 
been contributed by a higher incidence of NKTL and adult T-cell lymphoma/leuke-
mia (ATLL) in the Asian population.
3. Clinical aspects
3.1 Clinical characteristics
PTCL NOS is a disease of older adults with a median age of 60. It often presents 
at advanced stages with both nodal and extranodal sites of disease, with cutaneous 
and bone marrow involvement being the most common extranodal sites [5, 8].
Angioimmunoblastic T-cell lymphoma (AITL) is a multifaceted disease with 
a spectrum of clinical presentations, from fairly indolent disease to aggressive 
presentations. Similar to PTCL NOS, it is also a disease of older adults. Patients 
often present in advanced stages with B symptoms being the most common clinical 
manifestation. Bone marrow, liver, spleen, and skin involvements are common in 
this disease [9]. Immune-related phenomena such as hemolytic anemia, hypergam-
maglobulinemia, and positive Coombs test are associated with AITL [10].
Anaplastic large cell lymphomas (ALCL) are CD30-positive T-cell lymphoprolif-
erative disorders with about half having ALK gene rearrangement (ALK + ALCL). 
The ALK-positive variant occurs in young adults with a median age of 30, while 
the ALK-negative ALCL is a disease of older adults. Systemic ALCLs have a varying 
clinical course and prognosis compared to their cutaneous counterparts, with the 
latter having an indolent course of disease with long-term survival in the range of 
85–95% [11]. Central nervous system involvement is seen more commonly in ALCL 
than other T-cell lymphoma subtypes.
Extranodal NK-/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia 
are the different subtypes of NKTL. NKTL commonly involves the nasal cavity and 
the upper aerodigestive tract. While localized disease is often treated with curative 
intent, advanced disease is invariably fatal. A small proportion of advanced NKTL 
patients can present with hemophagocytic syndrome resulting in high fevers, cyto-
penias, coagulopathy, abnormal liver function tests, and very high ferritin levels.
Adult T-cell leukemia/lymphoma is a disease of adolescents and young adults. 
Extensive marrow involvement defines the leukemic variant of this disease, while 
the lymphoma variant has less than 20% marrow involvement. This is a highly 
aggressive disease with common presentations including bulky mediastinal masses 
or nodal disease [12].
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of disease, with 
mycosis fungoides and Sezary syndrome being the most common subtypes. The 
incidence of the various subtypes often increases with age [13]. CTCLs are generally 
indolent diseases, but large cell transformation is generally associated with poor 
outcomes [14].
3.2 Workup and diagnosis
Workup of T-cell lymphomas involves a complete history and physical examina-
tion followed by routine laboratory evaluation including full blood count, assessment 
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of end-organ function, lactate dehydrogenase levels, and screening for human 
immunodeficiency virus, hepatitis B and C. Epstein-Barr virus (EBV) DNA testing 
using EBV PCR can be considered in EBV-positive tumors. Plasma EBV detection can 
serve as a marker to monitor disease response and as a prognostic factor in these set-
tings [15]. Staging evaluations include radiological imaging and bone marrow biopsy 
[18]. Fluorodeoxyglucose positron emission tomography combined with computer 
tomography (PET CT) is gaining an increasing role in the initial staging of T-cell lym-
phomas. Given the high propensity for extranodal involvement, some of which (e.g., 
cutaneous involvement) may not be well demarcated on CT, PET CT may be useful as 
an initial staging modality. A retrospective study demonstrated that almost a third of 
the patients in the study had additional sites of disease picked up on PET CT beyond 
conventional CT imaging [16]. In NKTL, PET CT has been established as a standard 
staging investigation given its high sensitivity and specificity [17].
The diagnosis of T-cell lymphomas should ideally be made by a hematopatholo-
gist. An excisional biopsy is recommended whenever possible in order to ensure 
availability of adequate tissue sample for histopathological analysis. According to 
the WHO classification in 2008, the diagnosis of PTCL requires the integration of 
clinical, pathological, immunohistochemical, and molecular findings.
4. Management
At present there is no standard of care available for management of T-cell 
lymphoma as a result of paucity of randomized controlled phase 3 trials. 
Anthracycline-based regimens such as cyclophosphamide, vincristine, doxoru-
bicin, and prednisolone (CHOP) have been the backbone of treatment for many 
decades for most subtypes of T-cell lymphomas, with the exception of NKTL. The 
international T-cell lymphoma project, with a predominant European and 
Asian population, demonstrated that there was no survival benefit seen with an 
anthracycline-based regimen for PTCL NOS and AITL [5]. A subsequent retro-
spective study in a north American population showed 25 months improvement 
in survival with the use of an anthracycline-based regimen, even after controlling 
for confounding factors [18]. Nevertheless, unlike the B-cell counterparts, T-cell 
lymphomas in general have a poorer outcome, with 5-year overall survival being 
about 30%.
In NKTL, anthracycline-based regimens were abandoned early on with 
the discovery that NK cells have a high expression of multidrug-resistant 
P-glycoprotein. Hence, drugs that are transported by P-glycoproteins such as 
cyclophosphamide and doxorubicin become ineffective [19]. L-asparaginase is an 
enzyme that induces cytotoxicity to lymphoma/leukemic cells by catalyzing the 
hydrolysis of L-asparagine, thereby resulting in its depletion. This drug has been 
demonstrated to have significant in vitro activity against NK cells [20] and hence 
has been incorporated into the treatment regimens. Hence, in advanced NKTL, 
L-asparaginase-based multiagent chemotherapy has been adopted as first-line 
treatment.
4.1 Strategies to improve first-line treatment
4.1.1 Intensive chemotherapy
Multiple strategies have been explored in order to overcome the poor treatment 
outcomes in T-cell lymphomas. A retrospective study by MD Anderson group dem-
onstrated that more intensive regimens such as HyperCVAD and HyperCHOP did 
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not fare better than conventional CHOP in non-ALCL T-cell lymphomas. The 3-year 
overall survival was 49% in the intensive treatment group as compared to 43% in 
the CHOP group, and this was not statistically significant [21].
The GOELAMS-LTP95 was a phase 3 randomized trial that compared alternat-
ing cycles of VIP and rABVD (etoposide, ifosfamide, cisplatin—VIP; reinforced 
adriamycin, bleomycin, vinblastine, dacarbazine—rABVD) against CHOP for 
non-cutaneous T-cell lymphomas. There was no significant difference in the 2-year 
event-free survival, which was the primary endpoint of the study [22].
Gemcitabine, cisplatin, and methylprednisolone were compared to CHOP 
in the treatment of T-cell lymphomas in the first-line setting in a phase 2 trial. 
This CHEMO-T trial did not show any improvements in complete response rates, 
progression-free or overall survival rates between four cycles of GEM-P and 
six cycles of CHOP [23].
Hence, intensifying first-line chemotherapy as a strategy has not improved 
outcomes in T-cell lymphomas.
4.1.2 Addition of etoposide
The NHL B1 and B2 studies were designed to answer the questions of whether 
addition of etoposide to CHOP or increasing dose intensity of CHOP will improve 
outcomes in patients with aggressive lymphomas. T-cell lymphoma patients formed 
13.7 and 5.8% of the study populations in NHL B1 [24] and B2 [25] studies, respec-
tively. In young patients, addition of etoposide improved event-free survival by 
about 10%, but this did not translate into improvement in overall survival. In older 
patients, the addition of etoposide did not improve progression-free or overall 
survival compared to CHOP 14 which became the German standard of care follow-
ing the NHL B2 trial.
A retrospective review of patients treated in trials designed by the German 
non-Hodgkin lymphoma study group showed an improvement in 3-year event-free 
survival (EFS) from 51 to 75.1% (p = 0.03). However, this difference in EFS was 
predominantly contributed by the ALK-positive ALCL—the EFS in this subgroup 
improved markedly from 57.1 to 91.2% with the addition of etoposide. The differ-
ence in EFS was no longer statistically significant when this group was removed 
from the analysis [26].
Similar results were noted in a retrospective study by a Swedish group which 
analyzed 755 patients with T-cell lymphoma. Improvement in EFS was seen without 
a corresponding survival benefit [27].
A large retrospective study of 1933 Korean patients with T-cell lymphomas 
concluded that addition of etoposide had no progression-free or overall survival 
benefit, even in younger patients with good performance status. About 17% of 
the study population consisted of ALCL patients, but there was no differentiation 
between the ALK-positive and negative subtypes [28].
In summary, the benefit of etoposide comes through predominantly in the 
ALK-positive ALCL group. For the rest of T-cell lymphomas, etoposide is likely, and 
active agent and addition of this drug in younger patients remain an option, as long 
as toxicity can be minimized.
4.2 Role of upfront autologous transplant as consolidation
The PARMA study established the role of high-dose chemotherapy and autolo-
gous peripheral stem cell transplant (HDC and APSCT) in relapsed refractory 
B-cell lymphomas. Given the poor outcomes of T-cell lymphomas, this option was 
explored in T-cell lymphomas.
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One of the earliest prospective studies addressing the role of upfront APSCT in 
T-cell lymphoma was reported by Corradini et al. [29]. This Italian study reported 
long-term outcomes of two prospective phase 2 studies of patients with T-cell 
lymphoma treated with upfront HDC and APSCT. Sixty-two patients with stage 2 to 
4 T-cell lymphoma underwent two different conditioning regimens. Thirty percent 
of these patients had ALK-positive ALCL. Seventy-four percent of the patients 
underwent HDC and APSCT. Twelve-year overall survival and event-free survival 
with APSCT were 37 and 25%. ALK-positive ALCL patients had a significantly 
better survival than their other T-cell lymphoma counterparts. Achieving complete 
remission (CR) before APSCT was a strong predictor of improved survival in this 
study. Patients who achieved a CR before transplant had a 12-year DFS of 60% [29].
In another prospective single-arm study, 83 patients with PTCL, AITL, and 
ALK-negative ALCL as the predominant histologies were treated with 4–6 cycles 
of CHOP followed by HDC and APSCT. The 3-year OS and PFS were 48 and 36%, 
respectively. Eighty percent of patients relapsed within 24 months from APSCT [30].
The Nordic lymphoma group conducted a phase 2 prospective trial of 160 
patients with T-cell lymphoma, to determine the outcomes of dose-dense chemo-
therapy followed by HDC and APSCT. Patients were treated with three cycles of 
CHOPE (cyclophosphamide, doxorubicin, vincristine, prednisolone, and etoposide) 
every 14 days. In patients older than 60, etoposide was omitted—hence patients 
received dose-dense CHOP. Those who had partial or complete responses (PR or CR) 
went on to receive three more cycles of the same chemotherapy regimen followed by 
HDC and APSCT. Of note, ALK-positive ALCL patients were excluded. PTCL NOS 
patients were 39% of the cohort, followed by AITL and ALK-negative ALCL, each 
consisting of 19%. About 70% of patients underwent HDC and APSCT. The 5-year 
OS and PFS were 51 and 44%, respectively. The ALK-negative ALCL group had the 
highest 5-year OS of 70%. Toxicities of the dose-dense regimen were however not 
insignificant. Grades 3 and 4 hematological and non-hematological toxicity rates 
were 86 and 45%, respectively, with a treatment-related mortality of 4% [31].
While these studies seem to suggest a better outcome with upfront HDC and 
APSCT, compared to historical controls, the lack of a randomized comparison 
between upfront HDC and APSCT and conventional chemotherapy alone makes 
it difficult to establish this as standard of care. Given the absence of randomized 
trials, HDC and APSCT in first clinical remission (CR1) has been incorporated into 
guidelines. However, recent data is emerging to suggest that patients in CR1 may 
actually not benefit from HDC and APSCT.
A retrospective review of 105 patients who received CHOP-based chemotherapy 
as first-line was done. About 52.1% of the study population were in CR1. About 
half of these patients underwent HDC and APSCT, whereas the other half were on 
surveillance. At 22 months, the median PFS of the surveillance group compared to 
the group that underwent transplant was 15.8 months vs. 12.8 months, but this was 
not statistically significant. The authors hence concluded that patients who are in 
CR1 following induction chemotherapy may not benefit from APSCT [32].
Our group did a retrospective analysis of 175 patients from Singapore, South 
Korea, and China. PTCL NOS patients formed 42% of the cohort. AITL and 
ALK-negative ALCL formed 33% and 22% of the cohort, respectively. About 92% 
of patients received anthracycline-based induction chemotherapy. However, only 
18% of the cohort underwent upfront HDC and APSCT. Median PFS was 5.5 years 
for the entire population but OS was not reached. On multivariate analysis, age 
and advanced stage of disease were identified as poor prognostic factors. The use 
of anthracycline-based regimens as well as HDC and APSCT did not feature as 
significant factors affecting survival or progression-free survival outcomes, even in 
younger patients [33].
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These results were echoed in a multicenter retrospective study done in Europe. 
AITL was the most common subtype in this dataset (46%), compared to PTCL 
NOS (29%) and ALK-positive ALCL (25%). In order to eliminate selection bias in 
the retrospective analysis, multivariate proportional hazard model and propensity 
score matching model were both applied. Two-hundred sixty-nine patients were 
analyzed among whom half the patients had undergone HDC and APSCT at CR1 
and the other half was under surveillance. Five-year PFS and OS were 45% and 
60%, respectively, for the overall population. Consolidation APSCT at CR1 did not 
improve survival outcomes in this population. Once again, remission status (CR or 
PR) at the end of induction featured as a significant prognostic factor [34].
In summary, achieving a CR at the end of induction therapy is a crucial prognos-
tic factor in determining outcomes in TCL. The role of upfront autologous trans-
plant, especially in patients who have achieved CR1, remains to be defined.
4.3 Role of allogenic transplant in CR1
Two prospective studies attempted to explore the role of allogenic transplant in 
first remission [35, 36]. In both the studies, about 39% of patients did not undergo 
transplant, predominantly due to early progression. In the Italian study, only a 
quarter of the patients who underwent transplant remained in CR at 44 months. 
Hence, allogenic transplant as consolidation therapy is not recommended.
4.4 Relapsed or refractory disease
In the relapsed setting, autologous or allogenic transplant remains as options 
following salvage chemotherapy to attain a response. The Center for International 
Blood and Marrow Transplant Research reported 3-year PFS and OS rates of 41 and 
53%, respectively, for patients undergoing autologous transplant at first relapse. The 
rationale for allogenic transplant in lymphoma has been to harness the graft versus 
lymphoma effect. Three-year OS for myeloablative versus a non-myeloablative 
regimen was 31 and 50%, respectively. Once again, having a chemosensitive disease 
and having two lines of treatment or fewer were important prognostic factors for 
survival [37, 38].
4.5 Novel agents
4.5.1 Brentuximab vedotin
Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of a chi-
meric monoclonal antibody linked to an anti-tubulin agent, monomethyl auristatin 
E (MMAE). The monoclonal antibody targets CD30-expressing cells, and MMAE is 
released intracellularly to bind to tubulin. The binding of MMAE to tubulin disrupts 
the microtubule network, causing cell cycle arrest and apoptosis. Brentuximab 
vedotin is cell cycle phase-specific (G2/M phase). CD30 is uniformly expressed in 
anaplastic large cell lymphomas. In addition to that, about 43% of PTCL (excluding 
ALL) has been estimated to have CD30 expression [39].
A phase 2 study demonstrated a response rate of 41% when brentuximab was 
administered to CD30-positive T-cell lymphomas, at 1.8 mg/kg every 3 weeks. This 
study excluded ALCL patients. This was a considerable response given that 63% of 
patients were refractory to the most recent therapy prior to brentuximab. Interestingly, 
the degree of CD30 expression did not correlate with the responses [40].
A retrospective French study analyzed the effectiveness of brentuximab in 
56 patients. Twenty-four patients had ALCL. Cutaneous lymphomas (72%) and 
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ALCLs (62%) had better overall response rates than non-ALCL PTCLs (21%). 
Contrary to the study by Horwitz et al., this study reported a statistically significant 
improvement in PFS with stronger (>75%) expression of CD30 [41].
A prior study in JCO reported exceptional response rates of 86% with the use 
of brentuximab in relapsed refractory ALCL. The CR rates were 57% and median 
duration of response was 12.6 months. These excellent responses were demon-
strated despite 62% of patients having primary refractory disease [42].
The ALCANZA trial was a phase 3 trial that compared brentuximab against 
physician choice treatment for patients with cutaneous T-cell lymphomas who have 
seen prior treatment. This study demonstrated that patients who had brentuximab 
had better objective global response rates (56.3%) than those who had physician 
choice treatment (12.5%). The endpoint of objective global response comprised of 
response in the skin, node, viscera, and blood, lasting for a minimum of 4 months. 
The median progression-free survival was 16.7 months vs. 3.5 months HR 0.27 
(p < 0.0001). These results are certainly promising, especially given that this group 
of diseases has limited efficacious systemic treatment [43, 44].
The efficacy of brentuximab in the relapsed refractory settings has prompted 
the evaluation of this drug in the first-line setting. A phase 1 study explored the 
safety and efficacy of combining brentuximab with cyclophosphamide, doxoru-
bicin, and prednisolone (BV CHP) in 26 treatment naïve PTCL patients. Patients 
received six cycles of BV CHP followed by BV maintenance for up to 10 cycles. 
Seventy-three percent of the study population consisted of ALCL. One hundred 
percent response rate with 50% continuing to remain in CR at 5 years was reported. 
The predominant toxicity was peripheral neuropathy which resolved in the major-
ity. While the results are exciting, it is possible that the results were driven primarily 
by the ALCL population. A larger randomized study stratified by tumor subtypes 
will be important before this is adopted as the new standard of care [44].
Regardless, the promising efficacy of brentuximab, at least in the post first-line 
setting cannot be disregarded. This is generally a well-tolerated drug with predomi-
nant toxicities being peripheral neuropathy, myelosuppression, fatigue, and nausea.
4.5.2 Pralatrexate
Pralatrexate is a novel antifolate drug which inhibits dihydrofolate reductase 
enzyme, thereby inhibiting the conversion of dihydrofolate to tetrahydrofolate. 
Blocking this essential step in DNA and RNA synthesis results in cell cycle arrest. In 
addition, its high affinities for reduced folate carrier and folylpolyglutamate synthase 
are distinctive features that account for its superior activity compared to other drugs 
in the same class [45]. The early phase II-I-II study showed an overall response rate 
of 54% in TCL, compared to only 5% in B-cell lymphomas [46]. A weekly dose of 
30 mg/m2 for 6 out of 7 weeks had a better toxicity profile than a dose of  
135 mg/m2 given every other week. The PROPEL study which recruited 115 patients 
with TCL demonstrated an overall response rate of 29%. Eleven percent achieved 
CR. Of note, 5 out of 26 patients who were refractory to prior lines of therapy 
responded to this drug [47]. However, common toxicities of this drug include 
mucositis, fatigue, myelosuppression, and abnormal liver function tests.
4.5.3 Romidepsin
Romidepsin is predominantly a class 1 histone deacetylase inhibitor (HDAC). 
Through complex interactions, which remain to be fully understood, this drug dis-
rupts chromatin structure and activates transcription factors. As a result, it medi-
ates cell cycle arrest and cell death and increases transcription of tumor suppressor 
9© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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genes. In a pivotal phase 2 study, romidepsin was administered at 14 mg/m2  
on days 1 and 8 and 15 in a 28 days cycle, to patients with relapsed or refractory 
T-cell lymphoma. PTCL and AITL were the most common subtypes in the study. 
A 25% response rate was reported, with 15% achieving CR. Responses were also 
durable with median duration of response being 17 months [48]. Another phase 
2 study by the NCI group reported 38% response rates with duration of response 
being 8.9 months [49]. The main toxicities in both these studies were cytopenias, 
infections, fatigue, and nausea.
4.5.4 Belinostat
Belinostat is a pan-HDAC inhibitor which inhibits classes I, II, and IV HDAC. It 
facilitates apoptosis and cell cycle arrest in abnormal, transformed cells through 
complex interactions with cell cycle mechanisms. Based on a phase 2 trial which 
demonstrated 25% response rates in PTCL, the BELIEF (Belinostat in Patients With 
Relapsed or Refractory Peripheral T-Cell Lymphoma) trial was conducted. This was 
a single-arm study where belinostat was administered as an intravenous infusion at 
a dose of 1000 mg/m2 on days 1–5 Q21 days, to patients with relapsed or refractory 
T-cell lymphomas. The study reported a modest objective response rate of 26% with 
duration of response of 8.3 months. Of note, AITL patients had a higher response 
rate of 46% than 23% in PTCL patients. The main toxicities were fever, hematologi-
cal toxicities, nausea, and fatigue [50].
5. Conclusion
T-cell lymphoma has evolved from being one disease to a mixed bag of multiple 
diseases, each of which is being understood at greater depths now, with the advent 
of technology and molecular biology. With a better understanding of the disease 
biologies, the therapeutic armamentarium needs to be developed further in order to 
improve outcomes from these diseases.
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